Cargando…

Model-Informed Drug Development, Pharmacokinetic/Pharmacodynamic Cutoff Value Determination, and Antibacterial Efficacy of Benapenem against Enterobacteriaceae

Benapenem is a novel carbapenem. The objective of this study was to determine the pharmacokinetic (PK)/pharmacodynamic (PD) cutoff values and evaluate the optimal administration regimens of benapenem for the treatment of bacterial infections via PK/PD modeling and simulation. Ertapenem was used as a...

Descripción completa

Detalles Bibliográficos
Autores principales: Ji, Xi-wei, Xue, Feng, Kang, Zi-sheng, Zhong, Wei, Kuan, Isabelle Hui-san, Yang, Xi-ping, Zhu, Xiao, Li, Yun, Lv, Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7038265/
https://www.ncbi.nlm.nih.gov/pubmed/31844001
http://dx.doi.org/10.1128/AAC.01751-19
_version_ 1783500607571623936
author Ji, Xi-wei
Xue, Feng
Kang, Zi-sheng
Zhong, Wei
Kuan, Isabelle Hui-san
Yang, Xi-ping
Zhu, Xiao
Li, Yun
Lv, Yuan
author_facet Ji, Xi-wei
Xue, Feng
Kang, Zi-sheng
Zhong, Wei
Kuan, Isabelle Hui-san
Yang, Xi-ping
Zhu, Xiao
Li, Yun
Lv, Yuan
author_sort Ji, Xi-wei
collection PubMed
description Benapenem is a novel carbapenem. The objective of this study was to determine the pharmacokinetic (PK)/pharmacodynamic (PD) cutoff values and evaluate the optimal administration regimens of benapenem for the treatment of bacterial infections via PK/PD modeling and simulation. Ertapenem was used as a control. Infected mice received an intravenous (i.v.) injection of benapenem or ertapenem of 14.6, 58.4, or 233.6 mg/kg of body weight, and the PK/PD profiles were evaluated. The MICs were determined by using a 2-fold agar dilution method. Mathematical models were developed to characterize the pharmacokinetic profile of benapenem in humans and mice. Monte Carlo simulations were employed to determine the cutoff values and the appropriate benapenem dosing regimens for the treatment of infections caused by clinical isolates of Enterobacteriaceae. Two 2-compartment models were developed to describe the PK profiles of benapenem in humans and mice. A two-site binding model was applied to fit the protein binding in mouse plasma. Through correlation analysis, the percentage of the time that the free drug concentration remains above the MIC (%fT(>MIC)) was determined to be the indicator of efficacy. Results from the simulation showed that the probability of target attainment (PTA) against the tested isolates was over 90% with the dosing regimens studied. The PK/PD cutoff value of benapenem was 1 mg/liter at a %fT(>MIC) of 60% when given at a dose of 1,000 mg/day by i.v. drip for 0.5 h. The established model provides a better understanding of the pharmacological properties of benapenem for the treatment of Enterobacteriaceae infections. The proposed PK/PD cutoff value suggests that benapenem is a promising antibacterial against the Enterobacteriaceae. The cutoff value of 1 mg/liter may be a useful guide for the clinical use of benapenem and for surveillance for benapenem resistance.
format Online
Article
Text
id pubmed-7038265
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-70382652020-03-06 Model-Informed Drug Development, Pharmacokinetic/Pharmacodynamic Cutoff Value Determination, and Antibacterial Efficacy of Benapenem against Enterobacteriaceae Ji, Xi-wei Xue, Feng Kang, Zi-sheng Zhong, Wei Kuan, Isabelle Hui-san Yang, Xi-ping Zhu, Xiao Li, Yun Lv, Yuan Antimicrob Agents Chemother Experimental Therapeutics Benapenem is a novel carbapenem. The objective of this study was to determine the pharmacokinetic (PK)/pharmacodynamic (PD) cutoff values and evaluate the optimal administration regimens of benapenem for the treatment of bacterial infections via PK/PD modeling and simulation. Ertapenem was used as a control. Infected mice received an intravenous (i.v.) injection of benapenem or ertapenem of 14.6, 58.4, or 233.6 mg/kg of body weight, and the PK/PD profiles were evaluated. The MICs were determined by using a 2-fold agar dilution method. Mathematical models were developed to characterize the pharmacokinetic profile of benapenem in humans and mice. Monte Carlo simulations were employed to determine the cutoff values and the appropriate benapenem dosing regimens for the treatment of infections caused by clinical isolates of Enterobacteriaceae. Two 2-compartment models were developed to describe the PK profiles of benapenem in humans and mice. A two-site binding model was applied to fit the protein binding in mouse plasma. Through correlation analysis, the percentage of the time that the free drug concentration remains above the MIC (%fT(>MIC)) was determined to be the indicator of efficacy. Results from the simulation showed that the probability of target attainment (PTA) against the tested isolates was over 90% with the dosing regimens studied. The PK/PD cutoff value of benapenem was 1 mg/liter at a %fT(>MIC) of 60% when given at a dose of 1,000 mg/day by i.v. drip for 0.5 h. The established model provides a better understanding of the pharmacological properties of benapenem for the treatment of Enterobacteriaceae infections. The proposed PK/PD cutoff value suggests that benapenem is a promising antibacterial against the Enterobacteriaceae. The cutoff value of 1 mg/liter may be a useful guide for the clinical use of benapenem and for surveillance for benapenem resistance. American Society for Microbiology 2020-02-21 /pmc/articles/PMC7038265/ /pubmed/31844001 http://dx.doi.org/10.1128/AAC.01751-19 Text en Copyright © 2020 Ji et al. https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Experimental Therapeutics
Ji, Xi-wei
Xue, Feng
Kang, Zi-sheng
Zhong, Wei
Kuan, Isabelle Hui-san
Yang, Xi-ping
Zhu, Xiao
Li, Yun
Lv, Yuan
Model-Informed Drug Development, Pharmacokinetic/Pharmacodynamic Cutoff Value Determination, and Antibacterial Efficacy of Benapenem against Enterobacteriaceae
title Model-Informed Drug Development, Pharmacokinetic/Pharmacodynamic Cutoff Value Determination, and Antibacterial Efficacy of Benapenem against Enterobacteriaceae
title_full Model-Informed Drug Development, Pharmacokinetic/Pharmacodynamic Cutoff Value Determination, and Antibacterial Efficacy of Benapenem against Enterobacteriaceae
title_fullStr Model-Informed Drug Development, Pharmacokinetic/Pharmacodynamic Cutoff Value Determination, and Antibacterial Efficacy of Benapenem against Enterobacteriaceae
title_full_unstemmed Model-Informed Drug Development, Pharmacokinetic/Pharmacodynamic Cutoff Value Determination, and Antibacterial Efficacy of Benapenem against Enterobacteriaceae
title_short Model-Informed Drug Development, Pharmacokinetic/Pharmacodynamic Cutoff Value Determination, and Antibacterial Efficacy of Benapenem against Enterobacteriaceae
title_sort model-informed drug development, pharmacokinetic/pharmacodynamic cutoff value determination, and antibacterial efficacy of benapenem against enterobacteriaceae
topic Experimental Therapeutics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7038265/
https://www.ncbi.nlm.nih.gov/pubmed/31844001
http://dx.doi.org/10.1128/AAC.01751-19
work_keys_str_mv AT jixiwei modelinformeddrugdevelopmentpharmacokineticpharmacodynamiccutoffvaluedeterminationandantibacterialefficacyofbenapenemagainstenterobacteriaceae
AT xuefeng modelinformeddrugdevelopmentpharmacokineticpharmacodynamiccutoffvaluedeterminationandantibacterialefficacyofbenapenemagainstenterobacteriaceae
AT kangzisheng modelinformeddrugdevelopmentpharmacokineticpharmacodynamiccutoffvaluedeterminationandantibacterialefficacyofbenapenemagainstenterobacteriaceae
AT zhongwei modelinformeddrugdevelopmentpharmacokineticpharmacodynamiccutoffvaluedeterminationandantibacterialefficacyofbenapenemagainstenterobacteriaceae
AT kuanisabellehuisan modelinformeddrugdevelopmentpharmacokineticpharmacodynamiccutoffvaluedeterminationandantibacterialefficacyofbenapenemagainstenterobacteriaceae
AT yangxiping modelinformeddrugdevelopmentpharmacokineticpharmacodynamiccutoffvaluedeterminationandantibacterialefficacyofbenapenemagainstenterobacteriaceae
AT zhuxiao modelinformeddrugdevelopmentpharmacokineticpharmacodynamiccutoffvaluedeterminationandantibacterialefficacyofbenapenemagainstenterobacteriaceae
AT liyun modelinformeddrugdevelopmentpharmacokineticpharmacodynamiccutoffvaluedeterminationandantibacterialefficacyofbenapenemagainstenterobacteriaceae
AT lvyuan modelinformeddrugdevelopmentpharmacokineticpharmacodynamiccutoffvaluedeterminationandantibacterialefficacyofbenapenemagainstenterobacteriaceae